| Bioactivity | 5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation[1]. | ||||||||||||
| In Vivo | 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt[1].5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) reduces the symptoms and delayed the onset of EAE[1]. Animal Model: | ||||||||||||
| Name | 5J-4 | ||||||||||||
| CAS | 827001-82-1 | ||||||||||||
| Formula | C16H12N2O3S | ||||||||||||
| Molar Mass | 312.34 | ||||||||||||
| Appearance | Powder | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kim KD, et al. Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation. J Immunol. 2014 Jan 1;192(1):110-22. |